{
    "nctId": "NCT00259090",
    "briefTitle": "Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer",
    "officialTitle": "A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women.\n* Biopsy confirmation of primary breast cancer.\n* Oestrogen receptor positive tumour.\n* Fit for surgery within one month.\n* Written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Previous treatment with any anti-hormonal therapy for breast cancer.\n* Previous radiotherapy to the primary tumour.\n* Previous chemotherapy for the primary tumour.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}